July 17, 2026 11:52 pm (IST)
Follow us:
Dr Reddy's acquires rights to an investigational anti-cancer agent
Hyderabad, Mar 31 (IBNS) Dr Reddy's Laboratories, an integrated pharmaceutical company, announced on Thursday that it has entered into a licensing agreement with Eisai Company Limited of Japan, by which Dr Reddy's will be granted exclusive worldwide development and commercialization rights (excluding Japan and Asia) for Eisai's investigational anticancer agent E7777.
Eisai will develop and market E7777 in Japan and Asia; Dr Reddy's holds the option for rights to develop and market the agent in India, the company said.
In exchange of these rights, Eisai will receive milestone payments in line with obtaining marketing approval and the achievement of agreed upon sales targets.
Raghav Chari, Executive Vice President, Proprietary Products Group, Dr Reddy's Laboratories, said, "E7777 has significant potential as an important component of systemic therapy for cutaneous T-cell lymphoma (CTCL). This therapy represents an extension of our current efforts in the dermatology space to an important segment of skin-related cancers."
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Reliance Industries posts record quarterly revenue of ₹3.4 lakh crore, Jio IPO on the horizon
Fri, Jul 17 2026
TCS, Google Cloud launch Gemini Experience Center in Kolkata
Fri, Jul 17 2026
Uber makes massive $14.8 billion bet to take over Delivery Hero
Fri, Jul 17 2026
CEAT shares crash over 9% after tyre maker's Q1 profit plunges 96%
Fri, Jul 17 2026